Table 1.
Some selected immunotherapeutic agents (Anti- PDL-1) in clinical trials including the possible combination therapy.
| CT Number | Status | Phase | Condition | Sponsor | Additional agents |
|---|---|---|---|---|---|
| ATEZOLIZUMAB (PDL-1 INHIBITOR)- APPROVED BY FDA | |||||
| NCT02724878 | Recruiting | II | Non Clear Cell Kidney Cancer | Dana-Farber Cancer Institute | Bevacizumab |
| NCT02989584 | Recruiting | I, II | Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma | Memorial Sloan Kettering Cancer Center | Gemcitabine |
| Cisplatin | |||||
| NCT02302807 | Not yet recruiting | III | Bladder Cancer | Hoffmann-La Roche | Docetaxel |
| Paclitaxel | |||||
| Vinflunine | |||||
| NCT02708680 | Recruiting | I, II | Breast Cancer | Syndax Pharmaceuticals | Entinostat |
| NCT03023423 | Recruiting | I, II | Non-Small-Cell Lung Carcinoma | Janssen Research & Development, LLC | Daratumumab |
| NCT02716038 | Recruiting | II | Carcinoma, Non-Small-Cell Lung | Columbia University, Genentech, Inc., Celgene Corporation | MPDL3280A |
| Carboplatin | |||||
| Nab-paclitaxel | |||||
| NCT02814669 | Recruiting | I | Castrate-Resistant Prostate Cancer | Hoffmann-La Roche | Radium-223 dichloride |
| NCT02846623 | Recruiting | II | Chronic Lymphocytic Leukemia | M.D. Anderson Cancer Center | Obinutuzumab |
| Small Lymphocytic Lymphoma | |||||
| NCT02788279 | Recruiting | III | Colorectal Cancer | Hoffmann-La Roche | Cobimetinib |
| Regorafenib | |||||
| NCT02792192 | Recruiting | I, II | High-risk Non-muscle-invasive Bladder Cancer (NMIBC) | Hoffmann-La Roche | Biological: Bacille Calmette-Guérin |
| NCT02902029 | Recruiting | II | Malignant Melanoma | University Hospital, Essen | Vemurafenib |
| Cobimetinib | |||||
| NCT02908672 | Recruiting | III | Melanoma | Hoffmann-La Roche | Vemurafenib |
| NCT02924883 | Recruiting | II | Metastatic Breast Cancer | Hoffmann-La Roche | Trastuzumab |
| NCT02425891 | Recruiting | III | Metastatic Breast Cancer; TNBC | Hoffmann-La Roche | Nab-Paclitaxel |
| NCT03024437 | Not yet recruiting | I, II | Metastatic Cancer | Roberto Pili | Bevacizumab |
| Entinostat | |||||
| Renal Cancer | |||||
| NCT03013218 | Not yet recruiting | II | Metastatic Cancer; Solid Tumor; Advanced Cancer; Non-Hodgkin Lymphoma | Alexo Therapeutics, Inc. | Trastuzumab |
| NCT02657434 | Recruiting | III | NSCLC | Hoffmann-La Roche | Carboplatin |
| Pemetrexed | |||||
| Cisplatin | |||||
| NCT01903993 | Active-not recruiting | II | NSCLC | Hoffmann-La Roche | Docetaxel |
| NCT02008227 | Active, not recruiting | III | NSCLC | Hoffmann-La Roche | Docetaxel |
| NCT02367781 | Recruiting | III | Non-Squamous Non-Small Cell Lung Cancer | Hoffmann-La Roche | Carboplatin |
| Nab-paclitaxel | |||||
| ATEZOLIZUMAB (PDL-1 INHIBITOR)- APPROVED BY FDA | |||||
| NCT02366143 | Recruiting | III | NSCLC | Hoffmann-La Roche | Bevacizumab |
| Carboplatin | |||||
| Paclitaxel | |||||
| NCT02891824 | Recruiting | III | Ovarian Cancer | ARCAGY/GINECO GROUP | Avastin + platinum-based chemotherapy |
| NCT03038100 | Not yet recruiting | III | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms | Hoffmann-La Roche | Paclitaxel |
| Carboplatin | |||||
| Bevacizumab | |||||
| NCT02659384 | Recruiting | II | Ovarian Neoplasms | EORTC | Bevacizumab acetylsalicylic acid |
| NCT02992912 | Recruiting | II | Patients with Metastatic Tumors | Gustave Roussy, Cancer Campus, Grand Paris | SABR |
| NCT03016312 | Recruiting | III | Prostatic Neoplasms | Hoffmann-La Roche | Enzalutamide |
| Castration-Resistant | |||||
| NCT02873195 | Not yet recruiting | II | Recurrent Colorectal Carcinoma; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer | Academic and Community Cancer Research, (NCI) | Bevacizumab |
| Capecitabine | |||||
| NCT02926833 | Recruiting | II | Refractory Diffuse Large B Cell Lymphoma | Kite Pharma, Inc. Genentech, Inc. | Biological: KTE-C19 |
| NCT02420821 | Recruiting | III | Renal Cell Carcinoma | Hoffmann-La Roche | Bevacizumab |
| Sunitinib | |||||
| NCT02748889 | Recruiting | II | Small Cell Lung Cancer (SCLC) | Giuseppe Giaccone,Vanderbilt University, |Georgetown University | Etoposide MPDL3280A |
| NCT02763579 | Recruiting | III | Small Cell Lung Cancer | Hoffmann-La Roche | Carboplatin |
| Etoposide | |||||
| NCT02367794 | Recruiting | III | Squamous NSCLC | Hoffmann-La Roche | Carboplatin |
| Nab-paclitaxel | |||||
| NCT02409355 | Active, not recruiting | III | Squamous NSCLC | Hoffmann-La Roche | Carboplatin |
| Cisplatin | |||||
| NCT02807636 | Recruiting | III | Urothelial Carcinoma | Hoffmann-La Roche | Carboplatin |
| Gemcitabine | |||||
| Cisplatin | |||||
| NCT03029832 | Not yet recruiting | II | Urothelial Carcinoma | Genentech, Inc. | MOXR0916 |
| AVELUMAB (ANTI-PDL-1) APPROVED BY FDA | |||||
| NCT02875613 | Recruiting | II | Nasopharyngeal Cancer | Assuntina Sacco, M.D., Pfizer, University of California, San Diego | – |
| NCT02912572 | Not yet recruiting | II | Metastatic Endometrial Cancer | Dana-Farber Cancer Institute, Pfizer | – |
| NCT02915523 | Not yet recruiting | I, II | Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer | Syndax Pharmaceuticals Merck KGaA, Pfizer | Entinostat |
| NCT02953561 | Not yet recruiting | I, II | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia | M.D. Anderson Cancer Center, Pfizer | 5-azacytidine |
| NCT02943317 | Recruiting | II | Epithelial Ovarian Cancer | Verastem, Inc. | VS-6063 |
| NCT02994953 | Recruiting | II | Advanced Solid Tumors | Merck KGaA, EMD Serono | NHS-IL12 |
| NCT02952586 | Recruiting | III | Squamous Cell Carcinoma of the Head and Neck | Pfizer | Chemo-radiation |
| NCT02395172 | Recruiting | III | NSCLC | Merck KGaA, EMD Serono | Docetaxel |
| NCT02968940 | Not yet recruiting | II | Glioblastoma | New York University School of Medicine, EMD Serono | Radiation: (HFRT) |
| NCT02580058 | Recruiting | III | Ovarian Cancer | Pfizer | Biological: PLD |
| NCT02684006 | Recruiting | III | Renal Cell Cancer | Pfizer | Axitinib |
| Sunitinib | |||||
| NCT03035630 | Not yet recruiting | II | Clear-cell Renal Cell Carcinoma; | Guru Sonpavde, Hoosier Cancer Research Network, Pfizer | Sunitinib |
| NCT02625623 | Recruiting | III | Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line | Merck KGaA,EMD Serono | Irinotecan |
| Paclitaxel | |||||
| NCT02576574 | Recruiting | III | First Line NSCLC | Merck KGaA, EMD Serono | Pemetrexed |
| Paclitaxel | |||||
| Gemcitabine | |||||
| Carboplatin | |||||
| Cisplatin | |||||
| Carboplatin | |||||
| NCT02603432 | Recruiting | III | Urothelial Cancer | Pfizer | – |
| NCT02625610 | Recruiting | III | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Merck KGaA, EMD Serono | Oxaliplatin |
| 5-Fluorouracil | |||||
| Leucovorin | |||||
| Capecitabine | |||||
| PD 0360324 | |||||
| NCT02718417 | Recruiting | III | Ovarian Cancer | Pfizer | Carboplatin paclitaxel |
| NCT02584634 | Recruiting | II | NSCLC | Pfizer | |PF06463922 Crizotinib |
| NCT02951156 | Not yet recruiting | III | Diffuse Large B-Cell Lymphoma (DLBCL) | Pfizer, EMD Serono | Utomilumab |
| Rituximab | |||||
| Azacitidine | |||||
| Bendamustine | |||||
| Gemcitabine | |||||
| Oxaliplatin | |||||
Data taken from Clinicaltrials.gov website.